Evidence map›Paper›PMID 40977721›Full record

ArticleFrontiers in immunology2025

Antibodies elicited by altSonflex1-2-3 GMMA vaccine are bactericidal against a panel of drug-resistant

Elena Boero, Roberta Di Benedetto, Giacomo Vezzani, Renzo Alfini, Pieter-Jan Ceyssens, Giannoula S Tansarli, Ferric C Fang, Carla Fontana, Alberto Rossi, Stefania Carrara and 6 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Elena Boero *GSK Vaccines Institute for Global Health (GVGH), Siena, Italy.
Roberta Di Benedetto *GSK Vaccines Institute for Global Health (GVGH), Siena, Italy.
Giacomo VezzaniGSK Vaccines Institute for Global Health (GVGH), Siena, Italy.
Renzo AlfiniGSK Vaccines Institute for Global Health (GVGH), Siena, Italy.
Pieter-Jan CeyssensDivision of Human Bacterial Diseases, Sciensano, Brussels, Belgium.
Giannoula S TansarliDepartment of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, WA, United States.
Ferric C FangDepartment of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, WA, United States.
Carla FontanaLaboratory of Microbiology and Biological Bank, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
Alberto RossiLaboratory of Microbiology and Biological Bank, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
Stefania CarraraLaboratory of Microbiology and Biological Bank, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
Francesca ManciniGSK Vaccines Institute for Global Health (GVGH), Siena, Italy.
Miren IturrizaGSK Vaccines Institute for Global Health (GVGH), Siena, Italy.
Claudia SalaMonoclonal Antibody Discovery Laboratory, Fondazione Toscana Life Sciences, Siena, Italy.
Carlo GiannelliGSK Vaccines Institute for Global Health (GVGH), Siena, Italy.
Omar RossiGSK Vaccines Institute for Global Health (GVGH), Siena, Italy.
Francesca MicoliGSK Vaccines Institute for Global Health (GVGH), Siena, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Shigellosis significantly impacts global health, particularly affecting vulnerable populations in low- and middle-income countries, with over 270 million annual infections. It also causes morbidity in specific high-risk groups in high-income countries. Antibiotic treatment is increasingly compromised by multidrug-resistant strains, highlighting the urgent need for a

Indexed as

Antibodies, BacterialDysentery, BacillaryO AntigensShigellaShigella flexneriShigella sonneiShigella VaccinesAnimalsAnti-Bacterial AgentsDrug Resistance, Multiple, BacterialFemaleHumansMiceMice, Inbred BALB CAnti-Bacterial AgentsAntibodies, BacterialO AntigensShigella VaccinesaltSonflex1-2-3AMRGMMAO-antigenSBAShigellavaccine

Identifiers

PMID40977721
PMCPMC12443847

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.